You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Live Chat

Seretide evidence

Seretide efficacy and clinical evidence

Read the information below to understand the key clinical evidence for Seretide in asthma and COPD.

 

seretide-studies-overview

Asthma summary

Asthma patients uncontrolled on ≤ 500mcgs BDP or equivalent when stepped up to Seretide can
experience12

  • 88% of rescue medication free days over one year*
  • 74% of symptom free days over one year*
  • 75% patients achieved guideline-defined control after one year

* This was demonstrated in a post-hoc analysis of the GOAL study.12

Read the GOAL study summary below or the GOAL study in full

COPD summary

Short-term benefits

COPD patients on Seretide 500 Diskus experienced an improvement in:

  • lung function after 24 hours measured as PEFR vs. placebo, salmeterol and fluticasone propionate in a patient subgroup with baseline FEV1 <50% predicted (p<0.0001)3
  • breathlessness after 48 hours compared with placebo in a patient subgroup with baseline FEV1 <50% predicted (p<0.001)3

Long-term benefits

TORCH was a 3 year study. The primary endpoint of the effect of Seretide 500 Diskus on all-cause mortality did not meet statistical significance; P=0.0524

Additionally, over 3 years, COPD patients taking Seretide 500 Diskus experienced:

  • a 43% reduction in the rate of exacerbations requiring oral steroids compared with placebo (p<0.001) ARR = – 0.34 exacerbations/yr (0.46 Seretide 500 Diskus vs. 0.80 placebo)4
  • Improvement in quality of life measured with SGRQ4
  • Reduced rate of lung function decline by 16mL per year compared with placebo (in a post-hoc analysis) (p<0.001)5

Read the TORCH study summary below or the TORCH study in full

Evidence for Seretide in adults with asthma:

Go To Close Top

Gaining Optimal Asthma control The "GOAL" study summary 12

GOAL-summary


Evidence for Seretide 50/25 Evohaler or 100/50 Diskus in children with asthma:

De Blic et al. study summary 6

Evohaler-evidence

For further information on how Seretide offers an effective asthma treatment for children aged four years and older, see our Paediatrics page.


Evidence for Seretide 500/50 Diskus in adults with COPD 

TORCH (TOwards a Revolution in COPD Health) study summary4

torch-study

INSPIRE study summary7

inspire-study

Kardos et al. study summary8

Kardios-study

References:

  1. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am J Respir Crit Care Med. 2004; 170:836-844
  2. Woodcock AA et al; Prim Care Respir J. 2007; 16(3): 155-161
  3. Vestbo et al; ATS Poster 2003
  4. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2007; 356:775-789
  5. Celli et al; Am J Respir Crit Care Med; 2008; 178; 332-338
  6. De Blic J et al. Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children. Pediatr Allergy Immunol 2009
  7. Wedzicha JA et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177:19–26
  8. Kardos P et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:144–149

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

Seretide, Diskus and Evohaler are registered trademarks of the GlaxoSmithKline Group of Companies